Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-21231
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBurbuqe, Ibrahimi-
dc.contributor.authorBoettger, Soenke-
dc.contributor.authorSchubert, Maria-
dc.contributor.authorBettex, Dominique-
dc.contributor.authorRudiger, Alain-
dc.date.accessioned2021-01-11T09:23:11Z-
dc.date.available2021-01-11T09:23:11Z-
dc.date.issued2020-04-29-
dc.identifier.issn1478-9515de_CH
dc.identifier.issn1478-9523de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/21231-
dc.descriptionErworben im Rahmen der Schweizer Nationallizenzen (http://www.nationallizenzen.ch)de_CH
dc.description.abstractObjective: From case reports, haloperidol administration has been associated with QTc prolongation, torsades de pointes, and sudden cardiac death. In a vulnerable population of critically ill patients after cardiac surgery, however, it is unclear whether haloperidol administration affects the QTc interval. Thus, the aim of this study is to explore the effect of haloperidol in low doses on this interval. Method: This retrospective cohort study was performed on a cardio-surgical intensive care unit (ICU), screened 2,216 patients and eventually included 68 patients with delirium managed with oral and intravenous haloperidol. In this retrospective analysis, electrocardiograms were taken prior and within 24 h after haloperidol administration. The effect of haloperidol on QTc was determined with a Person correlation, and inter-group differences were measured with new long QT comparisons. Results: In total, 68 patients were included, the median age was 71 (64–79) years and predominantly male (77%). Haloperidol administration followed ICU admission by three days and the cumulative dose was 4 (2–9) mg. As a result, haloperidol administration did not affect the QTc (r = 0.144, p = 0.23). In total, 31% (21/68 patients) had a long QT before and 27.9% (19/68 patients) after haloperidol administration. Only 12% (8/68 patients) developed a newly onset long QT. These patients were not different in the route of administration, cumulative haloperidol doses, comorbidities, laboratory findings, or medications. Significance of results: These results indicated that low-dose intravenous haloperidol was safe and not clinically relevant for the development of a newly onset long QT syndrome or adverse outcomes and support recent findings inside and outside the ICU setting.de_CH
dc.language.isoende_CH
dc.publisherCambridge University Pressde_CH
dc.relation.ispartofPalliative & Supportive Carede_CH
dc.rightsLicence according to publishing contractde_CH
dc.subjectCardiac surgeryde_CH
dc.subjectDeliriumde_CH
dc.subjectHaloperidolde_CH
dc.subjectICUde_CH
dc.subjectLong QTde_CH
dc.subjectQTc timede_CH
dc.subject.ddc616: Innere Medizin und Krankheitende_CH
dc.titleQTc prolongation after haloperidol administration in critically ill patients post cardiovascular surgery : a cohort study and review of the literaturede_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementGesundheitde_CH
zhaw.organisationalunitInstitut für Pflege (IPF)de_CH
dc.identifier.doi10.1017/S1478951520000231de_CH
dc.identifier.doi10.21256/zhaw-21231-
dc.identifier.pmid32345400de_CH
zhaw.funding.euNode_CH
zhaw.issue4de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end459de_CH
zhaw.pages.start447de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume18de_CH
zhaw.embargo.end2026-01-01de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen Gesundheit

Show simple item record
Burbuqe, I., Boettger, S., Schubert, M., Bettex, D., & Rudiger, A. (2020). QTc prolongation after haloperidol administration in critically ill patients post cardiovascular surgery : a cohort study and review of the literature. Palliative & Supportive Care, 18(4), 447–459. https://doi.org/10.1017/S1478951520000231
Burbuqe, I. et al. (2020) ‘QTc prolongation after haloperidol administration in critically ill patients post cardiovascular surgery : a cohort study and review of the literature’, Palliative & Supportive Care, 18(4), pp. 447–459. Available at: https://doi.org/10.1017/S1478951520000231.
I. Burbuqe, S. Boettger, M. Schubert, D. Bettex, and A. Rudiger, “QTc prolongation after haloperidol administration in critically ill patients post cardiovascular surgery : a cohort study and review of the literature,” Palliative & Supportive Care, vol. 18, no. 4, pp. 447–459, Apr. 2020, doi: 10.1017/S1478951520000231.
BURBUQE, Ibrahimi, Soenke BOETTGER, Maria SCHUBERT, Dominique BETTEX und Alain RUDIGER, 2020. QTc prolongation after haloperidol administration in critically ill patients post cardiovascular surgery : a cohort study and review of the literature. Palliative & Supportive Care. 29 April 2020. Bd. 18, Nr. 4, S. 447–459. DOI 10.1017/S1478951520000231
Burbuqe, Ibrahimi, Soenke Boettger, Maria Schubert, Dominique Bettex, and Alain Rudiger. 2020. “QTc Prolongation after Haloperidol Administration in Critically Ill Patients Post Cardiovascular Surgery : A Cohort Study and Review of the Literature.” Palliative & Supportive Care 18 (4): 447–59. https://doi.org/10.1017/S1478951520000231.
Burbuqe, Ibrahimi, et al. “QTc Prolongation after Haloperidol Administration in Critically Ill Patients Post Cardiovascular Surgery : A Cohort Study and Review of the Literature.” Palliative & Supportive Care, vol. 18, no. 4, Apr. 2020, pp. 447–59, https://doi.org/10.1017/S1478951520000231.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.